Matrix interference in ligand-binding assays: challenge or solution?

“One of the key characteristics in ligand binding assays that requires detailed attention is the understanding of the difference between selectivity (matrix effect) and specificity (cross-reactivity).” Ligand binding assays (LBAs) still remain the workhorse for the quantification of biotherapeutics and biomarkers. These molecules include, but are not limited to, proteins, large peptides, soluble receptors, antibody–drug conjugates and oligonucleotides. Many of the molecules that are of therapeutic use are biologically derived, and the structure–function relationship can be unique and complex. Alternatively, those that are considered biomarkers can be bound to other molecules that serve a specific function. Hence, the accurate quantification...